Related Experiment Video
Updated: Apr 27, 2026
07:09
A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
Published on: February 18, 2022
2.2K
Natriuretic peptides in heart failure with preserved ejection fraction
A Mark Richards1, James L Januzzi2, Richard W Troughton3
1Cardiac Department, Cardiovascular Research Institute, National University Heart Centre, National University of Singapore, 1E Kent Ridge Road, NUHS Tower Block, Level 9, Singapore 119228, Singapore; Department of Medicine, Christchurch Heart Institute, University of Otago, Christchurch, 2 Riccarton Avenue, Christchurch 8140, New Zealand.
Heart Failure Clinics
|July 1, 2014
Summary
Cardiac natriuretic peptides (NPs) aid heart failure (HF) management. This review focuses on the specific evidence and application of NPs in heart failure with preserved ejection fraction (HFPEF).
Area of Science:
- Cardiology
- Biomarkers
- Heart Failure Research
Background:
- Effective heart failure (HF) management relies on timely diagnosis, risk stratification, and treatment optimization.
- Cardiac natriuretic peptides (NPs) are established biomarkers in general HF care.
- Limited data exist on NP utility specifically in heart failure with preserved ejection fraction (HFPEF).
Purpose of the Study:
- To review the existing evidence for the use of natriuretic peptides (NPs) in HFPEF.
- To clarify the role and application of NPs in the evaluation and management of HFPEF patients.
Main Methods:
- Literature review of studies investigating natriuretic peptides (NPs) in heart failure with preserved ejection fraction (HFPEF).
- Synthesis of data on NP performance and clinical utility in HFPEF diagnosis, risk stratification, and treatment guidance.
Main Results:
- Evidence suggests NPs are valuable in assessing HFPEF, though less extensively studied than in HFREF.
- NPs can aid in differentiating HFPEF from other conditions and in risk stratification.
- Optimal therapeutic strategies guided by NPs in HFPEF require further investigation.
Conclusions:
- Natriuretic peptides (NPs) show promise as diagnostic and prognostic tools in heart failure with preserved ejection fraction (HFPEF).
- Further research is needed to define the best clinical applications and therapeutic implications of NPs in HFPEF management.
Related Concept Videos
01:29Heart Failure II: Pathophysiology
1.7K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.7K
01:22Heart Failure Drugs: Diuretics
1.5K
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.5K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
1.7K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.7K
01:30Heart Failure V: Medical Management
621
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
621
01:22Heart Failure Drugs: β-Blockers
2.6K
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
2.6K
01:17Hormonal Regulation of Blood Pressure
7.6K
Endocrinal or hormonal intervention in the cardiovascular system is predominantly exerted by the catecholamines - epinephrine and norepinephrine, as well as a slew of hormones that interact with renal function to modulate blood volume.
Epinephrine and Norepinephrine
The adrenal medulla releases epinephrine and norepinephrine, catecholamines that enhance and extend the sympathetic or "fight or flight" physiological response. These hormones escalate heart rate and the force of contraction...
Epinephrine and Norepinephrine
The adrenal medulla releases epinephrine and norepinephrine, catecholamines that enhance and extend the sympathetic or "fight or flight" physiological response. These hormones escalate heart rate and the force of contraction...
7.6K